Merck RotaTeq Approval Will Bring Spring Shower Of Disease Awareness Ads
Executive Summary
Merck will begin a targeted disease awareness print and internet advertising campaign this spring as part of the launch of the rotavirus vaccine RotaTeq
You may also be interested in...
Menactra Returns To Normal Schedule; FluMist Seeks CDC Contract
FluMist CDC contract: MedImmune is negotiating a contract with the Centers for Disease Control & Prevention to supply its intranasal flu vaccine FluMist for the 2006-2007 season, VP & General Manager Mark Twyman says during a Oct. 25-26 meeting of CDC's Advisory Committee on Immunization Practices in Atlanta. The firm could supply the entire pediatric market by the 2008-2009 season, he says. Firm plans to produce 3 mil. doses of FluMist for the U.S. market for the current season and expects to have production, filling and distribution capacity for 20 mil. to 30 mil. doses for 2008-2009. MedImmune hopes to launch its refrigerator-stable version, CAIV-T (cold adapted influenza vaccine, trivalent), by next season. The firm hopes the non-freezer version will boost sluggish uptake...
Menactra Returns To Normal Schedule; FluMist Seeks CDC Contract
FluMist CDC contract: MedImmune is negotiating a contract with the Centers for Disease Control & Prevention to supply its intranasal flu vaccine FluMist for the 2006-2007 season, VP & General Manager Mark Twyman says during a Oct. 25-26 meeting of CDC's Advisory Committee on Immunization Practices in Atlanta. The firm could supply the entire pediatric market by the 2008-2009 season, he says. Firm plans to produce 3 mil. doses of FluMist for the U.S. market for the current season and expects to have production, filling and distribution capacity for 20 mil. to 30 mil. doses for 2008-2009. MedImmune hopes to launch its refrigerator-stable version, CAIV-T (cold adapted influenza vaccine, trivalent), by next season. The firm hopes the non-freezer version will boost sluggish uptake...
RotaTeq recommended
Merck's rotavirus vaccine RotaTeq was recommended for use by the Centers for Disease Control & Prevention's Advisory Committee on Immunization Practices Feb. 21. The committee voted 12-0 with two abstentions for routine immunization of infants with three doses of the oral vaccine to be administered at two, four and six months of age. CDC analysis found that RotaTeq was not cost effective at the published price of $62 per dose, but could be cost effective at $42 per dose. RotaTeq was approved in early February (1"The Pink Sheet" Feb. 12, 2006, p. 25)...